Phase 3 N=306 Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
Male Hypogonadism
Primary: Serum Testosterone Cavg — 76; 43; 61 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=418 A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
Chronic Kidney Disease (CKD)
Primary: Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL) — 61.9330; 63.3305 Percentage of Weeks
Phase 3 N=772 A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Plaque Psoriasis
Primary: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) — 62.3; 63.8; 5.8 Percentage of Participants — p=<0.001
Phase 3 N=1,164 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · Connective Tissue Disease · Autoimmune Disease
Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 31.8; 35.2; 29.3 percentage of participants
Phase 3 N=248 A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Cystic Fibrosis
Primary: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8 — -0.3; 4.4; 6.5 percentage of…
Phase 3 N=168 A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Cystic Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 — -0.1; 1 Percentage of predicted FEV1 — p== 0.1176
Phase 3 N=3,527 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Urinary Bladder Overactive · Urinary Bladder Diseases\Urologic Diseases · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.34; -1.70; -1.76; -1.79 incontinence episodes — p=0.072
Phase 3 N=210 Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Renal Cancer
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR
Phase 3 N=510 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
Cystic Fibrosis
Primary: Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24 — -0.6; 3.4 Percentage of predicted FEV1…
Phase 3 N=2,014 A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension — 3; 6; 1; 0…
Phase 3 N=634 A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol — 2.6 g/dL — p=<0.0001
Phase 3 N=812 A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 252; 5; 386; 7 Participants — p=<0.0001
Phase 3 N=567 Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm — 88.6; 92.4 percentage of participants — p=0.15
Phase 3 N=605 A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 291; 117; 327; 145 Participants — p=0.2833
Phase 3 N=758 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Multiple Myeloma
Primary: Percentage of Participants With Progression-free Survival (PFS) — 58.5; 57.8; 53.9 percentage of participants — p=0.87